microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome

BACKGROUND: Gastrointestinal stromal tumour (GIST) is mainly initialised by receptor tyrosine kinase gene mutations. Although the tyrosine kinase inhibitor imatinib mesylate considerably improved the outcome of patients, imatinib resistance still remains a major therapeutic challenge in GIST therapy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Akçakaya, P, Caramuta, S, Åhlen, J, Ghaderi, M, Berglund, E, Östman, A, Bränström, R, Larsson, C, Lui, W-O
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4260040/
https://ncbi.nlm.nih.gov/pubmed/25349971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.548
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars